DENdritic Cell Immunotherapy for Mesothelioma

• Status: Recruiting
• Trial end date: 2023-02-15
• Target enrollment: 0
• Participant gender: All

Summary

This study is to evaluate the overall survival (OS) rate (determined from the time of randomization in the study) of subjects who receive dendritic cell immunotherapy with MesoPher plus best supportive care (BSC) compared to BSC alone.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Amphera BV
• Collaborator: TMC Pharma

Criteria

Subjects will only be included with a histologically confirmed diagnosis of pleural malignant mesothelioma, who are non-progressive after 4 to 6 cycles with first line chemotherapy with antifolate/platinum.